💡 Did you know?
The BSE, founded in 1875, is Asia's oldest stock exchange — it started under a banyan tree on Dalal Street, where the bronze bull stands today.
History
The BSE, founded in 1875, is Asia's oldest stock exchange — it started under a banyan tree on Dalal Street, where the bronze bull stands today.
The BSE, founded in 1875, is Asia's oldest stock exchange — it started under a banyan tree on Dalal Street, where the bronze bull stands today.
Concord Biotech Limited is an India-based research and development-driven biopharma company. The Company is engaged in the research and development, manufacturing, marketing, and selling of pharmaceutical products. Its business verticals include active pharmaceutical…
Weekly engine runs — movement reflects the numbers, not analyst opinion.
A middling, stagnant business, fairly priced.
Concord Biotech is scored on the pharma / healthcare framework. It keeps a fat 23.4% of every rupee of sales as net profit. Cash broadly tracks reported profit (CFO/PAT 1.03×). Free cash flow is worth about 0.9% of its market value.
Over the last 3 years revenue compounded at 8%/yr and profit at 3%/yr. Book value itself has compounded 16%/yr — the hallmark of a genuine compounder. Return on equity is a healthy 13.6%. In the latest quarter profit grew 21% versus the prior quarter.
At 51× earnings, the stock sits at the 44th percentile of its own 3.3-year range — the middle of where it has historically traded. Today's price already implies ~21%/yr earnings growth sustained for a decade — a demanding bar. The books come through clean — a forensic grade of A, and Altman puts distress risk in the safe zone.
A plain-English restatement of the figures on this page — rules-based, for education and research context, not investment advice or a recommendation.
| Ratio | Company | Sector | Read |
|---|---|---|---|
| P/E | 47.35 | — | — |
| P/B | 6.37 | 4.1 | worse |
| EV/EBITDA | 31.33 | 19.33 | worse |
| ROE | 13.61 | — | — |
| ROCE | 18.02 | 14.41 | better |
| ROA | 12.01 | — | — |
| Quick Ratio | 5.46 | 4.8 | better |
| Peer | P/E | P/B | ROE |
|---|---|---|---|
| Sun Pharmaceutical Industries | 40.6 | 5.0 | 13.8% |
| Divis Laboratories | 93.5 | 16.3 | 15.3% |
| Torrent Pharmaceuticals | 85.9 | 9.8 | 11.4% |
Revenue is on a 2-year growth streak. 8% CAGR — growing but slowly. Growth is decelerating — latest year grew slower than the year before.
Profit is on a 2-year growth streak. Revenue is outpacing profit (8% vs 3%) — costs are rising faster than the top line. The latest year saw a -30% swing — check if it's a one-off or structural.
Operating margin has compressed from 36% to 31% — costs or competition are eating into profitability.
ROE at 13% — a respectable return on shareholder capital. Capital efficiency declining — ROE down 6pp.
EPS dropped in the latest year despite possible profit changes — dilution or a profit dip could be at play. 3% EPS CAGR — this is the rate at which each share's claim on earnings is compounding.
Operating cash flow has been positive every year — the business generates real cash, not just accounting profit. Heavy investing spend every year, but operations generate enough to cover it — the business self-funds its growth. Financing outflows in consecutive years — balance-sheet discipline through debt repayment or dividends.
When operating cash keeps pace with reported profit, earnings are cash-backed; a persistent shortfall is a quality flag.
Revenue rose 18% sequentially — momentum is building.
Profit jumped 21% QoQ — check if this is operating leverage or a one-off item.
How today's P/E compares to the stock's own historical range. Dashed line = the 3.3y median.
Promoters at 44.1% — dispersed ownership; institutional flows drive the stock.
Produced by a rules-based engine over licensed exchange fundamentals — every sentence above is derived from the numbers shown, no analyst or AI opinion involved. Education and research context, not investment advice. We are not SEBI-registered as an Investment Adviser or Research Analyst.